

Subject city, state	Effective date	Subject city, state	Effective date
GREENVILLE, AL WAGHER, LISA KATHLEEN ...	05/20/2003	CLEVELAND, OH MARTINEZ, JOSE R .....	05/20/2003
WILLIAMS, AZ WASSIF, ANTHONY A .....	05/20/2003	MINEOLA, TX	
RESEDSA, CA WEINBERG, ROBERT PAUL ..	05/20/2003	<b>OWNERS OF EXCLUDED ENTITIES</b>	
BOSTON, MA WEINBERG, MARC .....	05/20/2003	PARKER, CHARLIE A .....	05/20/2003
COLUMBIA, MD WHITE, MARGARET .....	05/20/2003	MINNEAPOLIS, MN PARKER, ROBERTA CATO ....	05/20/2003
ASHEVILLE, NC WILSON, JOHN STROTHER ...	05/20/2003	MINNEAPOLIS, MN	
MONTGOMERY, AL WILTFANG, CHRIS CHARLES	05/20/2003	<b>CIVIL MONETARY PENALTY</b>	
ST SIMONS ISLAND, GA WITTRUP, LADONNA	05/20/2003	MATTHYS, JERRY A .....	10/01/2002
ALBERTINA .....	05/20/2003	SHAWNEE MISSION, KS	
GREELEY, CO		Dated: May 1, 2003.	
<b>FEDERAL/STATE EXCLUSION/ SUSPENSION</b>		<b>Katherine B. Petrowski,</b> <i>Director, Exclusions Staff Office of Inspector General.</i>	
NATHAN, SYLVESTER AR- THUR .....	05/20/2003	[FR Doc. 03-11681 Filed 5-14-03; 8:45 am]	
WOODRIDGE, IL		<b>BILLING CODE 4150-04-P</b>	
NATOLI, DENNIS .....	05/20/2003	<b>DEPARTMENT OF HEALTH AND HUMAN SERVICES</b>	
RIVER EDGE, NJ	05/20/2003	<b>National Institutes of Health</b>	
SMOOTS, OLIVIA L .....	05/20/2003	<b>Government-Owned Inventions; Availability for Licensing</b>	
SACRAMENTO, CA		<b>AGENCY:</b> National Institutes of Health, Public Health Service, DHHS.	
<b>OWNED/CONTROLLED BY CONVICTED ENTITIES</b>		<b>ACTION:</b> Notice.	
BLOSSOM HILL DENTAL CARE .....	05/20/2003	<b>SUMMARY:</b> The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.	
SAN JOSE, CA CALIXTO GARCIA MEDICAL CTR INC .....	05/20/2003	<b>ADDRESSES:</b> Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/ 496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.	
MIAMI, FL DIAMOND DENTAL SERV- ICES, LLP .....	05/20/2003	<b>Triggering Receptors Expressed in Myeloid Cells (TREM) Like Transcript (TLT-1), A Novel Inhibitory Receptor of Platelets and Uses Therefore</b>	
POCATELLO, ID FAMILY FIRST HEALTHCARE, INC .....	05/20/2003	Daniel W. McVicar (NCI), A. Valence Washington (NCI), Laura Quigley (NCI)	
WICHITA, KS HOI LEE D D S .....	05/20/2003		
RENTON, WA NAT'L MEDICAL EQUIP & SUPPLIES .....	05/20/2003		
PLANTATION, FL PRINCIPLE MEDICAL MGMT, INC .....	05/20/2003		
HOLLYWOOD, CA ROLYJANE HOME CARE, INC	05/20/2003		
MIAMI, FL SOLOMON'S INVALID COACH, INC .....	05/20/2003		
NEWARK, NJ UNION PHARMACY .....	05/20/2003		
MIAMI, FL			
<b>DEFAULT ON HEAL LOAN</b>			
BARBATO, BEVERLY V .....	04/03/2003		
SALEM, WV BILYEU, STUART WILLIAM ....	05/20/2003		
ANN ARBOR, MI CROW, JOE A .....	05/20/2003		
ROCKY FORD, CO DIEDE, CLYDE A .....	05/20/2003		
WINNER, SD FLEMING, JAMES E JR .....	05/20/2003		
E CLEVELAND, OH LESINSKI, MARY CATHERINE	04/14/2003		

DHHS Reference No. E-097-2003/0  
filed March 16, 2003

*Licensing Contact:* Jeff Walenta; 301/  
435-4633; [walentaj@od.nih.gov](mailto:walentaj@od.nih.gov).

The human immune response involves a complex series of molecular interactions to produce a beneficial response to foreign invasion within the body. These molecular interactions orchestrate the specific responses of innate and adaptive immunity. When these interactions break down, immune related disorders such as cancer and sepsis arise.

This invention describes an advance in understanding the regulation of the immune response. Triggering Receptors in Myeloid Cells (TREM) recently were discovered to modulate innate and adaptive immunity. Specifically, TREM1 amplifies the response to sepsis in innate immunity by activating neutrophils and other leukocytes; and TREM2 potentiates dendritic cell maturation in adaptive immunity. This invention describes a new inhibitory TREM like Transcript, TLT-1.

TLT-1 is the first inhibitory receptor discovered to reside within the TREM gene locus. This discovery implies the receptor has an important regulatory role in both innate and adaptive immunity. Structurally, TLT-1 also possesses inhibitory domains that indicate this regulatory function. TLT-1 is highly expressed in peripheral blood platelets and may modulate many other types of myeloid cells. Potential therapeutic implications are for immune disorders, cancer, septic shock, infectious disease, stroke, heart disease, myocardial infarction, vascular disorders, and other platelet-associated disorders.

#### 17-AAG Treatment of Diseases Sensitive to c-KIT Down Regulation

Gerard Fumo and Len Neckers (NCI)  
DHHS Reference No. E-256-2002 filed  
22 Oct 2002

*Licensing Contact:* George Pipia; 301/  
435-5560; [pipiag@od.nih.gov](mailto:pipiag@od.nih.gov).

This invention describes the use of 17-allylamino-17-demethoxygeldanamycin (17-AAG), a derivative of geldanamycin, which inhibits mutated KIT protein kinase activity (the product of proto-oncogene c-KIT). This kinase has been identified as the protein responsible for transformation of certain human cell types into pathologic cells. The invention is predicated on the discovery of a new method of inhibiting the activity of a mutated, constitutively active form of the tyrosine kinase, KIT. The method involves the administration of 17-AAG to a cell expressing the